Imexpharm (STC:IMP) Shiller PE Ratio: (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫37,650.00
GF Value ₫48,426.49
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Imexpharm Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imexpharm  (STC:IMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Imexpharm Shiller PE Ratio Related Terms


Imexpharm Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Imexpharm's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Shiller PE Ratio Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.36 24.76 21.91 0.00 0.00

Imexpharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 40.33 0.00 40.03 0.00

STC:IMP vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Imexpharm's Shiller PE Ratio falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Imexpharm's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Imexpharm's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Imexpharm Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 199.910 241.428 276.523
201612 212.173 241.432 293.481
201703 206.469 243.801 282.816
201706 198.085 244.955 270.053
201709 170.209 246.819 230.297
201712 161.354 246.524 218.577
201803 221.042 249.554 295.797
201806 181.359 251.989 240.349
201809 234.633 252.439 310.396
201812 150.927 251.233 200.620
201903 212.187 254.202 278.756
201906 190.542 256.143 248.423
201909 320.346 256.759 416.656
201912 303.495 256.974 394.409
202003 244.156 258.115 315.892
202006 280.519 257.797 363.386
202009 273.160 260.280 350.478
202012 402.133 260.474 515.572
202103 266.234 264.877 335.663
202106 281.818 271.696 346.393
202109 178.788 274.310 217.661
202112 399.591 278.802 478.634
202203 300.433 287.504 348.970
202206 257.143 296.311 289.808
202209 307.792 296.808 346.311
202212 187.263 296.797 210.706
202303 429.545 301.836 475.250
202306 479.545 305.109 524.878
202309 420.000 307.789 455.701
202312 436.000 306.746 474.670
202403 373.000 312.332 398.820
202406 0.000 314.175 0.000
202409 404.000 315.301 427.898
202412 0.000 315.605 0.000
202503 431.000 319.799 450.074
202506 0.000 322.561 0.000
202509 429.000 324.800 441.088
202512 0.000 324.054 0.000
202603 474.000 330.213 479.367
202606 0.000 333.952 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫37,650.00 is trading 22.3% below its estimated GF Value™ of ₫48,426.49. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Shiller PE Ratio:
  • GF Value™: ₫48,426.49 vs. price of ₫37,650.00 (22.3% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫37,650.00
Price
₫48,426.49
GF Value